Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 5/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 4/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994572 | 1.00 | NT5E (0.34) | NT5ERIPK1HTR2AHTR2CPIM1 | |
| SCHEMBL23995368 | 0.85 | KCNJ6 (0.39) | NT5ERIPK1PIM1PIM3PIM2 | |
| SCHEMBL23994573 | 0.82 | NT5E (0.36) | NT5ERIPK1PIM1PIM3PIM2 | |
| SCHEMBL23994564 | 0.81 | HTR2A (0.39) | HTR2AHTR2CMAPK1 | |
| SCHEMBL23994600 | 0.80 | PDE10A (0.35) | HTR2AHTR2C | |
| SCHEMBL23994565 | 0.80 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL23994561 | 0.79 | RIPK1 (0.34) | NT5ERIPK1PIM1PIM3PIM2 | |
| SCHEMBL23995271 | 0.79 | HTR2A (0.39) | HTR2AHTR2CMAPK1 | |
| SCHEMBL23995512 | 0.78 | NT5E (0.36) | NT5ERIPK1PIM1PIM3PIM2 | |
| SCHEMBL25004508 | 0.77 | HTR2A (0.33) | HTR2AHTR2CMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | NT5E 3/4885RIPK1 3077/4885HTR2A 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.